OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press81410.17650/1818-8346-2023-18-2-25-34HEMATOLOGIC MALIGNANCIES: TREATMENTЛЕЧЕНИЕ ГЕМОБЛАСТОЗОВImmune checkpoint inhibitors in pediatric hematologic malignanciesИнгибиторы иммунных контрольных точек при опухолевых заболеваниях системы крови у детейhttps://orcid.org/0000-0001-7757-318XGribkovaI. V.ГрибковаИ. В.
Russian Federation

Irina Vladimirovna Gribkova

9 Sharikopodshipnikovskaya St., Moscow 115088, Russia 

Ирина Владимировна Грибкова 

Россия, 115088 Москва, ул. Шарикоподшипниковская, 9

igribkova@yandex.ruResearch Institute for Healthcare Organization and Medical Management, Moscow Healthcare DepartmentГБУ г. Москвы «Научно-исследовательский институт организации здравоохранения и медицинского менеджмента Департамента здравоохранения г. Москвы»300520231821003202327052023https://oncohematology.abvpress.ru/ongm/article/view/814

The use of immune checkpoint inhibitors as therapy in adult patients with malignancy has resulted in an improvement in overall survival. Research on the use of these drugs in pediatric oncology is just beginning. However, the results already obtained indicate the possibility of successful use of checkpoint inhibitors in children with Hodgkin’s lymphoma and some subtypes of non-Hodgkin’s lymphomas. This review analyzes the results of studies on the use of nivolumab and pembrolizumab for the treatment of children with lymphomas. The search for available literature sources was carried out in the databases PubMed, Scopus, eLibrary, Cyberleninka. The review also addresses the issue of possible predictors of response to immune checkpoint inhibitor therapy in children.

Использование ингибиторов иммунных контрольных точек в качестве терапии взрослых пациентов со злокачественными новообразованиями привело к увеличению общей выживаемости. Исследования применения данных препаратов в детской онкологии только начинаются. Однако уже полученные результаты свидетельствуют о возможности успешного применения ингибиторов иммунных контрольных точек у детей с лимфомой Ходжкина и некоторыми вариантами неходжкинских лимфом. В данном обзоре проанализированы результаты исследований применения ниволумаба и пембролизумаба для лечения детей с лимфомами. Поиск доступных источников литературы осуществляли в базах данных PubMed, Scopus, eLibrary, Cyberleninka. Также в обзоре рассматривается вопрос о возможных предикторах ответа на терапию ингибиторами иммунных контрольных точек у детей.

immune checkpoint inhibitornivolumabpembrolizumabhemoblastoseslymphomachildrenингибитор иммунных контрольных точекниволумабпембролизумабгемобластозылимфомадетиTarhini A., Lo E., Minor D.R. Releasing the brake on the immune system: Ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm 2010;25(6):601–13. DOI: 10.1089/cbr.2010.0865Chen D.S., Mellman I. Oncology meets immunology: the cancerimmunity cycle. Immunity 2013;39(1):1–10. DOI: 10.1016/j.immuni.2013.07.012Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252–64. DOI: 10.1038/nrc3239Ribas A., Wolchok J.D. Cancer immunotherapy using checkpoint blockade. Science 2018;359(6382):1350–5. DOI: 10.1126/science.aar4060Robert C., Long G.V., Brady B. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372(4):320–30. DOI: 10.1056/NEJMoa1412082Brahmer J., Reckamp K.L., Baas P. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373(2):123–35. DOI: 10.1056/NEJMoa1504627Ansell S.M., Lesokhin A.M., Borrello I. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015;372(4):311–9. DOI: 10.1056/NEJMoa1411087Younes A., Santoro A., Shipp M. et al. Nivolumab for classical Hodgkin’ lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016;17(9):1283–94. DOI: 10.1016/S1470-2045(16)30167-XChen R., Zinzani P.L., Fanale M.A. et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35(19):2125–32. DOI: 10.1200/JCO.2016.72.1316Armand P., Shipp M.A., Ribrag V.et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 2016;34(31):3733–9. DOI: 10.1200/JCO.2016.67.3467Xie W., Medeiros L.J., Li S. et al. PD-1/PD-L1 Pathway and its blockade in patients with classic Hodgkin lymphoma and non-Hodgkin large-cell lymphomas. Curr Hematol Malig Rep 2020;15(4):372–81. DOI: 10.1007/s11899-020-00589-yZinzani P.L., Ribrag V., Moskowitz C.H. et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood 2017;130(3):267–70. DOI: 10.1182/blood-2016-12-758383Nayak L., Iwamoto F.M., LaCasce A. et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood 2017;129(23):3071–3. DOI: 10.1182/blood-2017-01-764209Chan T.S., Khong P.L., Kwong Y.L. Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety. Ann Hematol 2016;95(11):1913–5. DOI: 10.1007/s00277-016-2764-1Rigaud C., Abbou S., Minard-Colin V. et al. Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma. Pediatr Blood Cancer 2018;65(4). DOI: 10.1002/pbc.26902Hebart H., Lang P., Woessmann W. Nivolumab for refractory anaplastic large cell lymphoma: a case report. Ann Intern Med 2016;165(8):607–8. DOI: 10.7326/L16-0037Davis K.L., Fox E., Merchant M.S. et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncol 2020;21(4):541–50. DOI: 10.1016/S1470-2045(20)30023-1Geoerger B., Kang H.J., Yalon-Oren M. et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial. Lancet Oncol 2020;21(1):121–33. DOI: 10.1016/S1470-2045(19)30671-0Kozlov A.V., Kazantsev I.V., Yukhta T.V. et al. The use of checkpoint inhibitors in children with non-Hodgkin lymphomas. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology 2020;19(2):112–20. (In Russ.). DOI: 10.24287/1726-1708-2020-19-2-112-120Козлов А.В., Казанцев И.В., Юхта Т.В. и др. Использование ингибиторов контрольных точек у детей с неходжкинскими лимфомами. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2020;19(2):112–20. DOI: 10.24287/1726-1708-2020-19-2-112-120Kozlov A.V., Kazantzev I.V., Iukhta T.V. et al. Nivolumab in pediatric Hodgkin’s lymphoma. Cell Ther Transplant 2019;8(4):41–8. DOI: 10.18620/ctt-1866-8836-2019-8-4-41-48Kelly K.M., Daw S., Mauz-Körholz C. et al. Response-adapted treatment with nivolumab and brentuximab vedotin (BV) in children, adolescents and young adults (CAYA) with relapsed/refractory classical Hodgkin lymphoma (R/R cHL): CheckMate 744 subgroup analyses. Hematol Oncol 2019;S307. DOI:10.1002/hon.26_2629MarjaŃska A., Drogosiewicz M., Dembowska-BagiŃska B. et al. Nivolumab for the Treatment of advanced pediatric malignancies. Anticancer Res 2020;40(12):7095–100. DOI: 10.21873/anticanres.14738Foran A.E., Nadel H.R., Lee A.F. et al. Nivolumab in the treatment of refractory pediatric hodgkin lymphoma. J Pediatr Hematol Oncol 2017;39(5):e263–6. DOI: 10.1097/MPH.0000000000000703Kassa C., Reményi P., Sinkó J. et al. Successful nivolumab therapy in an allogeneic stem cell transplant child with post-transplant lymphoproliferative disorder. Pediatr Transplant 2018;22(8):e13302. DOI: 10.1111/petr.13302Samoa R.A., Lee H.S., Kil S.H., Roep B.O. Anti-PD-1 therapyassociated type 1 diabetes in a pediatric patient with relapsed classical Hodgkin lymphoma. Diabetes Care 2020;43(9):2293–5. DOI: 10.2337/dc20-0740Tsaplina N.S., Valiev T.T., Petrova G.D. et al. Modern approaches in relapsed and refractory Hodgkin lymphoma treatment: literature review and own experience. Sovremennaya onkologiya = Journal of Modern Oncology 2022;24(3):319–24. (In Russ.). DOI: 10.26442/18151434.2022.3.201816Цаплина Н.С., Валиев Т.Т., Петрова Г.Д. и др. Современные подходы к лечению рецидивов и рефрактерных форм лимфомы Ходжкина: обзор литературы и собственные данные. Современная онкология 2022;24(3):319–24. DOI: 10.26442/18151434.2022.3.201816Belyaeva E.S., Susuleva N.A., Valiev T.T. The importance of intensive chemotherapy for advanced Hodgkin lymphoma in children. RMZH. Mat’ i ditya = Russian Journal of Woman and Child Health 2020;3(2):149–53. (In Russ.).Беляева Е.С., Сусулева Н.А., Валиев Т.Т. Значение интенсивной химиотерапии для лечения детей с распространенными стадиями лимфомы Ходжкина. РМЖ. Мать и дитя 2020;3(2):149–53.Harker-Murray P., Leblanc T., Mascarin M. et al. Responseadapted therapy with nivolumab and brentuximab vedotin (BV), followed by BV and bendamustine for suboptimal response, in children, adolescents, and young adults with standard-risk relapsed/refractory classical Hodgkin lymphoma. Blood 2018;132 (Suppl 1):927. DOI: 10.1182/blood-2018-99-111279Masucci G.V., Cesano A., Hawtin R. et al. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I – preanalytical and analytical validation. J Immunother Cancer 2016;4:76. DOI: 10.1186/s40425-016-0178-1Moskowitz C.H., Nademanee A., Masszi T. et al. Brentuximab vedotin as consolidation therapy after autologous stemcell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;385(9980):1853–62. DOI: 10.1016/S0140-6736(15)60165-9Borghaei H., Paz-Ares L., Horn L. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373(17):1627–39. DOI: 10.1056/NEJMoa1507643Roemer M.G.M., Advani R.H., Ligon A.H. et al. PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J Clin Oncol 2016;34(23):2690–7. DOI: 10.1200/JCO.2016.66.4482Lepik K.V. Immune checkpoint inhibitors in the treatment of lymphomas. Klinicheskaya onkogematologiya = Clinical Oncohematology 2018;11(4):303–12. (In Russ.). DOI: 10.21320/2500-2139-2018-11-4-303-312Лепик К.В. Ингибиторы иммунных контрольных точек в терапии лимфом. Клиническая онкогематология 2018;11(4):303–12. DOI: 10.21320/2500-2139-2018-11-4-303-312Gibney G.T., Weiner L.M., Atkins M.B. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 2016;17(12):e542–51. DOI: 10.1016/S1470-2045(16)30406-5Paré L., Pascual T., Seguí E. et al. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. Ann Oncol 2018;29(10):2121–8. DOI: 10.1093/annonc/mdy335Yearley J.H., Gibson C., Yu N. et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res 2017;23(12):3158–67. DOI: 10.1158/1078-0432.CCR-16-1761Martens A., Wistuba-Hamprecht K., Geukes Foppen M. et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 2016;22(12):2908–18. DOI: 10.1158/1078-0432.CCR-15-2412Meyers D.E., Stukalin I., Vallerand I.A. et al. The lung immune prognostic index discriminates survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors. Cancers (Basel) 2019;11(11):1713. DOI: 10.3390/cancers11111713Maibach F., Sadozai H., Seyed Jafari S.M. et al. Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front Immunol 2020;11:2105. DOI: 10.3389/fi mmu.2020.0210Nelson M.A., Ngamcherdtrakul W., Luoh S.W., Yantasee W. Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer. Cancer Metastasis Rev 2021 Jun;40(2):519–36. DOI: 10.1007/s10555-021-09968-0Liu S., Foulkes W.D., Leung S. et al. Prognostic significance of FOXP3+ tumor infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res 2014;16(5):432. DOI: 10.1186/s13058-014-0432-8Tokito T., Azuma K., Kawahara A. et al. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer 2016;55:7–14. DOI: 10.1016/j.ejca.2015.11.020Sade-Feldman M., Kanterman J., Klieger Y. et al. Clinical significance of circulating CD33+CD11b+HLA-DR-myeloid cells in patients with stage iv melanoma treated with ipilimumab. Clin Cancer Res 2016;22(23):5661–72. DOI: 10.1158/1078-0432.CCR-15-3104Hause R.J., Pritchard C.C., Shendure J., Salipante S.J. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 2016;22(11):1342–50. DOI: 10.1038/nm.4191Davis K.L., Agarwal A.M., Verma A.R. Checkpoint inhibition in pediatric hematologic malignancies. Pediatr Hematol Oncol 2017;34(6–7):379–94. DOI: 10.1080/08880018.2017.1383542Kiselevsky M.V., Samoylenko I.V., Zharkova O.V. et al. Predictive biomarkers of inhibitors immune checkpoints therapy in malignant tumors. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2021;8(2):73–83. (In Russ.). DOI: 10.21682/2311-1267-2021-8-2-73-83Киселевский М.В., Самойленко И.В., Жаркова О.В. и др. Прогностические биомаркеры эффективности иммунотерапии злокачественных новообразований ингибиторами контрольных точек иммунного ответа. Российский журнал детской гематологии и онкологии 2021;8(2):73–83. DOI: 10.21682/2311-1267-2021-8-2-73-83Janus G.A., Ievleva A.G., Suspitsyn E.N. et al. Predictive response markers for immune response blocks. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2020;19(4):123–31. (In Russ.). DOI: 10.21294/1814-4861-2020-19-4-123-131Янус Г.А., Иевлева А.Г., Суспицын Е.Н. и др. Предиктивные маркеры ответа на блокаторы контрольных точек иммунного ответа. Сибирский онкологический журнал 2020;19(4):123–31. DOI: 10.21294/1814-4861-2020-19-4-123-131